Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s). This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. This enzyme is highly similar in primary structure to the enzyme encoded by the UBE2L3 gene. Two alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.
ubiquitin-conjugating enzyme E2L 6
UBE2L6, Ubiquitin carrier protein L6, Ubiquitin-protein ligase L6, UBCH8, RIG-B
Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. Krmer OH, Mller S, Buchwald M, Reichardt S, Heinzel T. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2008 22:1369-79.
Related Antibodies: LS-C99504.